UB Paderborn / Katalog / Suche / in CDI

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet (British edition), 2014-08, Vol.384 (9941), p.414-426

2014

Volltextzugriff (PDF)

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2014-08, Vol.384 (9941), p.403-413

2014

Volltextzugriff (PDF)

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study

Hepatology (Baltimore, Md.), 2016-08, Vol.64 (2), p.370-380

2016

Volltextzugriff (PDF)

Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor

Journal of medicinal chemistry, 2014-03, Vol.57 (5), p.1673-1693

2014

Volltextzugriff (PDF)

Phase 1 Trial of the Safety, Pharmacokinetics, and Antiviral Activity of EDP-514 in Untreated Viremic Chronic Hepatitis B Patients

Clinical and molecular hepatology, 2024-07, Vol.30 (3), p.375-387

2024

Volltextzugriff (PDF)

Impact of Timing of Diagnosis of Respiratory Syncytial Virus (RSV) Disease on Hospital Length of Stay (LOS) in Adults: Final Analysis from a Retrospective Chart Review Study

Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S577-S578

2017

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial

AIDS Research and Treatment, 2012-01, Vol.2012, p.186987-10

2012

Volltextzugriff (PDF)

Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks

AIDS patient care and STDs, 2011-06, Vol.25 (6), p.333

2011

Volltextzugriff (PDF)

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)

Hepatology (Baltimore, Md.), 2016-08, Vol.64 (2), p.360-369

2016

Volltextzugriff (PDF)

Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial

Gastroenterology (New York, N.Y. 1943), 2014-06, Vol.146 (7), p.1669-1679.e3

2014

Volltextzugriff (PDF)

EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor: final results of a 28-day phase 1b study in nuc-suppressed chronic hepatitis B patients

Journal of hepatology, 2022-07, Vol.77, p.S848

2022

Volltextzugriff (PDF)

EDP-514, a potent pangenotypic class II hepatitis B virus core inhibitor, demonstrates significant HBV DNA and HBV RNA reductions in a phase 1b study in viremic, chronic hepatitis B patients

Journal of hepatology, 2022-07, Vol.77, p.S849

2022

Volltextzugriff (PDF)

Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks

AIDS research and human retroviruses, 2010-12, Vol.26 (12), p.1279

2010

Volltextzugriff (PDF)

EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B

Antiviral therapy, 2022-12, Vol.27 (6), p.135965352211278-13596535221127848

2022

Volltextzugriff (PDF)

Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks

AIDS research and human retroviruses, 2012-10, Vol.28 (10), p.1184

2012

Volltextzugriff (PDF)

Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients

Clinical and molecular hepatology, 2024-07, Vol.30 (3), p.375

2024

Volltextzugriff (PDF)

Native Valve Endocarditis Due to Bartonella henselae in a Middle-Aged Human Immunodeficiency Virus-Negative Woman

Journal of Clinical Microbiology, 2001-09, Vol.39 (9), p.3417-3419

2001

Volltextzugriff (PDF)

Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study

Clinical infectious diseases, 2014-12, Vol.59 (11), p.1579-1587

2014

Volltextzugriff (PDF)

Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients

Antiviral therapy, 2013, Vol.18 (3), p.289-300

2013

Volltextzugriff (PDF)

Why START? Reflections that led to the conduct of this large long‐term strategic HIV trial

HIV medicine, 2015-04, Vol.16 (S1), p.1-9

2015

Volltextzugriff (PDF)

Pharmacoeconomics of darunavir

Expert review of pharmacoeconomics & outcomes research, 2011-02, Vol.11 (1), p.27-39

2011

Volltextzugriff (PDF)

A Case of Strongyloides stercoralis and Mesenteric Tuberculous Infection with Acute Abdominal Pain in an HIV-positive Patient

Scandinavian journal of infectious diseases, 2002, Vol.34 (9), p.696-697

2002

Volltextzugriff (PDF)

Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial

HIV clinical trials, 2016-03, Vol.17 (2), p.72-77

2016

Volltextzugriff (PDF)

Development of Diagnostic Criteria for Serious Non-AIDS Events in HIV Clinical Trials

HIV clinical trials, 2010-07, Vol.11 (4), p.205-219

2010

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study

Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor

Phase 1 Trial of the Safety, Pharmacokinetics, and Antiviral Activity of EDP-514 in Untreated Viremic Chronic Hepatitis B Patients

Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy

Impact of Timing of Diagnosis of Respiratory Syncytial Virus (RSV) Disease on Hospital Length of Stay (LOS) in Adults: Final Analysis from a Retrospective Chart Review Study

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial

Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)

Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial

EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor: final results of a 28-day phase 1b study in nuc-suppressed chronic hepatitis B patients

EDP-514, a potent pangenotypic class II hepatitis B virus core inhibitor, demonstrates significant HBV DNA and HBV RNA reductions in a phase 1b study in viremic, chronic hepatitis B patients

Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks

EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B

Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks

Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients

Native Valve Endocarditis Due to Bartonella henselae in a Middle-Aged Human Immunodeficiency Virus-Negative Woman

Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study

Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients

Why START? Reflections that led to the conduct of this large long‐term strategic HIV trial

Pharmacoeconomics of darunavir

A Case of Strongyloides stercoralis and Mesenteric Tuberculous Infection with Acute Abdominal Pain in an HIV-positive Patient

Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial

Development of Diagnostic Criteria for Serious Non-AIDS Events in HIV Clinical Trials

Suchergebnisse filtern